Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Stock Information for Solid Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Solid Biosciences Inc.

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.